Evidence map›Paper›PMID 34440326›Full record

ArticleGenes2021

Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features.

Zoltán Pozsonyi, Gergely Peskó, Hedvig Takács, Dorottya Csuka, Viktória Nagy, Ágnes Szilágyi, Lidia Hategan, Balázs Muk, Beáta Csányi, Noémi Nyolczas and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07689331 (Hungarian National Systemic Amyloidosis Registry), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07689331 recruitingnot on this mapstarted 2026, after this paper: background citation

Hungarian National Systemic Amyloidosis Registry (AMYREG) - A Multi-Center, Longitudinal, Observational Survey of Patients With Systemic Amyloidosis

Typeobservational_patient_registrySponsorSemmelweis UniversityRan2026 to 2028Enrolled300ConditionsSystemic Amyloidosis, ATTR Amyloidosis, AL Amyloidosis, Amyloid Cardiomyopathy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Zoltán PozsonyiDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.
Gergely PeskóDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.
Hedvig TakácsDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Dorottya CsukaDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.ORCID 0000-0003-3610-9852
Viktória NagyDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Ágnes SzilágyiDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.ORCID 0000-0002-9769-3215
Lidia HateganDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Balázs MukMilitary Hospital-State Health Centre, H-1134 Budapest, Hungary.
Beáta CsányiDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Noémi NyolczasGottsegen National Cardiovascular Center, H-1096 Budapest, Hungary.
Lívia DézsiDepartment of Neurology, University of Szeged, H-6725 Szeged, Hungary.
Judit Mária MolnárInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, H-1088 Budapest, Hungary.ORCID 0000-0001-9350-1864
Anita CsillikDepartment of Neurology, Semmelweis University, H-1088 Budapest, Hungary.
Katalin RévészDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.
Béla IványiDepartment of Pathology, University of Szeged, H-6725 Szeged, Hungary.
Fruzsina SzabóInstitute of Genomic Medicine and Rare Disorders, Semmelweis University, H-1088 Budapest, Hungary.
Krisztián BirtalanDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Tamás MassziDepartment of Internal Medicine and Haematology, Semmelweis University, H-1088 Budapest, Hungary.
Zsuzsanna ArányiDepartment of Neurology, Semmelweis University, H-1088 Budapest, Hungary.
Róbert SeppDivision of Non-Invasive Cardiology, Department of Internal Medicine, University of Szeged, H-6725 Szeged, Hungary.
Semmelweis University · HUUniversity of Szeged · HUGottsegen National Cardiovascular Center · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVariant transthyretin amyloidosis (ATTRv) is an autosomal dominant inherited disease, where the mutation of the transthyretin gene (TTR) results in the deposition of pathogenic protein fibrils in various tissues. The mutation type influences the clinical course. Until now, no data were available on the genotype, phenotype, and prevalence of Hungarian ATTRv patients. The aim of our study was to assess the prevalence, regional distribution, genotypes, and phenotypes of Hungarian patients with ATTRv.

methodsWith the collaboration of Hungarian regional and university centers, we identified patients diagnosed with ATTRv. We also searched prior publications for case studies of Hungarian ATTRv patients.

results40 individuals in 23 families with ATTRv were identified within the borders of Hungary. At the time of the diagnosis, 24 of them were symptomatic. The two most common mutations were ATTRHis88Arg (nine families) and ATTRIle107Val (8 families). ATTRVal30Met was demonstrated in 2 families, and ATTRVal122del, ATTRPhe33Leu, ATTRIle84Ser, and ATTRAsp18Gly in one family each. The median age of the symptomatic patients at the time of clinical diagnosis was 65 years. The most common clinically significant organ involvement was restrictive cardiomyopathy, found in 24 patients. Polyneuropathy was diagnosed in 20 patients. A total of 19 patients showed a mixed phenotype. The leading symptom was heart failure in 8 cases (3 of them had only cardiac symptoms), polyneuropathy in 11 cases (all of them also had cardiac symptoms), and equally severe cardiac and neuropathy symptoms were present in 3 cases. Out of 24 symptomatic patients, 10 received targeted pharmacological therapy. The follow-up period ranged from 1 to 195 months. At the time of the retrospective analysis, 12 patients had already died, and 1 patient underwent heart transplantation.

conclusionsAs TTR genotype influences the phenotype and clinical course of ATTRv, it is important to know the regional data. In Hungary, ATTRHis88Arg and ATTRIle107Val are the most common mutations in ATTRv, both presenting with mixed phenotype, but the median age at the time of the diagnosis is 9 years lower in patients with ATTRHis88Arg than in patients with ATTRIle107Val.

Indexed as

AdultAgedAmyloid Neuropathies, FamilialFemaleHumansHungaryMaleMiddle AgedPrevalenceamyloidosisATTRHis88Argheart failurepolyneuropathytransthyretinvariant

Identifiers

PMID34440326
PMCPMC8392019
OpenAlexW3184416162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.